Mr. Hayim Raclaw reports

ALZAI AND LINUS HEALTH EXPLORE AI-DRIVEN COLLABORATIONS AIMED AT EARLY IDENTIFICATION OF ALZHEIMER'S DISEASE RISK AND COGNITIVE IMPAIRMENT

Alzai Health Corp. has entered into a memorandum of understanding (MOU) with Linus Health, an artificial-intelligence-driven brain health company focused on early detection and proactive intervention. The companies intend to explore opportunities to use their complementary technologies to support earlier identification and assessment of Alzheimer's disease risk and cognitive impairment, as well as related triage and care pathways.

Alzai and Linus will look at ways to combine Alzai's AI-driven Alzheimer's disease risk identification algorithm with Linus Health's Radar risk stratification algorithm, digital cognitive assessments and clinical decision support. Potential applications include integrated solutions supporting clinical trial recruitment, financed research initiatives, health care provider engagement and dementia care workflows.

The two risk-stratification approaches draw on complementary data already available in health records. Alzai's algorithm uses routine bloodwork and demographic data already present in the medical record to stratify disease risk without requiring a new test. Linus Health's Radar (Risk of Alzheimer's and Dementia AlgoRithm) builds on and improves the published and validated eRadar model, using electronic health record (EHR) and/or claims data that include diagnostic, medication and health-care-utilization signals. Linus Health's Core Cognitive Evaluation (CCE), which incorporates the Digital Clock and Recall (DCR), can then assess current cognitive performance, with results and recommended next steps returned to the clinician within the existing care workflow.

The collaboration will focus on opportunities with pharmaceutical companies, contract research organizations (CROs), health care providers, health care systems and research institutions to improve patient identification, optimize clinical trial recruitment, support clinical workflow integration, and advance earlier identification of individuals at elevated risk for Alzheimer's disease.

"We believe meaningful innovation in Alzheimer's disease requires collaboration across complementary technologies," said Hayim Raclaw, chief executive officer of Alzai Health. "Linus Health has established itself as a leader in digital cognitive assessment and brain health solutions. We believe that combining their capabilities with Alzai's AI-driven disease-risk identification algorithm could support the development of more integrated solutions. We look forward to exploring commercial and research opportunities that could advance earlier identification and patient care."

As part of the collaboration framework, Alzai and Linus Health also plan to evaluate opportunities for technical integration, joint commercialization initiatives, financed research programs, grant applications and future strategic agreements designed to accelerate adoption of AI-driven solutions across the Alzheimer's disease ecosystem.

"Risk stratification works best when it can use the signals already available in a patient's record," said Ali Jannati, MD, PhD, director of cognitive science at Linus Health. "Alzai uses routine blood tests, complementing our Radar algorithm, which draws on electronic health records or claims data. Together, these approaches can identify patients at elevated risk of Alzheimer's and other dementias who may benefit from cognitive evaluation. Linus Health's cognitive assessments and clinical decision support can then help translate earlier identification into earlier care."

The MOU is non-binding; any commercial arrangement or other definitive agreement arising from the collaboration will be subject to separate negotiation and the execution of definitive agreements by the parties.

About Alzai Health Corp.

Alzai Health is a health care technology company developing non-invasive, artificial-intelligence-driven disease risk identification solutions using routine health care data. The company's proprietary platform is designed to identify individuals at elevated risk for disease before clinical diagnosis, enabling earlier intervention opportunities and supporting improved patient outcomes. Alzai's technology has been validated on large-scale health care data sets and is designed for integration into existing health care infrastructure, including electronic medical record systems, cloud-based environments and enterprise health care platforms.

About Linus Health

Linus Health is a Boston-based digital health company focused on improving brain health around the world. The company develops science-driven digital assessments and AI-enabled analytics that help clinicians and researchers identify cognitive change earlier, guide next steps in care, and support more pro-active, personalized intervention. Linus Health works with health care delivery organizations, research institutions, and life sciences partners to advance earlier detection and better brain health outcomes.

We seek Safe Harbor.